Novel and Emerging Pharmacologic Treatments for Schizophrenia

Schizophrenia has been treated for more than 70 years with dopamine receptor antagonists or partial agonists, whose efficacy is thought to be related to a reduction of postsynaptic dopamine transmission. These so-called first- and second-generation ”antipsychotics” have been foundational for the management of schizophrenia and psychosis in general, but treatment gaps remain. These include insufficient efficacy for residual/resistant positive symptoms, negative symptoms and cognitive dysfunction, tolerability issues, and low rates of functional recovery. Several new treatments not targeting dopamine receptors directly have been superior to placebo for total, negative, and cognitive symptoms of schizophrenia. This video discusses what the challenges we have with the available Schizophrenia treatments today are? And what clinicians should keep in mind when considering the emerging treatment options for their patients living with Schizophrenia?
-
Read our full article on Novel and Emerging Pharmacologic Treatments for Schizophrenia: neurotorium.or...
-
Christoph U Correll, MD
- The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA
- Charité - Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany
-
Chapters:
00:00-01:56 - What are the challenges we have with the available Schizophrenia treatments today?
01:56-04:35 - What should clinicians keep in mind when considering the emerging treatment options for their patients living with Schizophrenia?